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ABSTRACT
Objective: Increasing prevalence and poor survival of advanced incurable non-small cell lung cancer (NSCLC) make it a major health problem globally, 
especially in developing countries. This awakens need for identification of the strongest prognostic factor that helps in the selection of appropriate 
treatment and hence palliates symptoms and improves survival. Lung cancer treatment guidelines advise performance status (PS) as the most 
established prognostic factor in advanced NSCLC patients. This study investigated the prognostic significance of PS.
Methods: An observational study was done for 163 advanced NSCLC adult Malaysian patients in Radiotherapy and Oncology Clinic, Hospital Kuala 
Lumpur, Malaysia. Demographic and clinical data were recorded. Kaplan-Meier test was used to measure median overall survival (OS) and Cox 
proportional hazard model to calculate the hazard ratio for different categories of Eastern Cooperative Oncology Group (ECOG) PS.
Results: The mean age and body weight were 56.7±10.1 years old and 57.42±13.5 kg, respectively. Majority patients were male (68.7%), Stage IV 
NSCLC (65.0%), and ECOG PS score of 2 (41.1%). ECOG PS had a significant association with age and body weight. Median OS was least for ECOG PS 
score of 4 (253 days) and was statistically significant (p=0.003). ECOG PS was a significant independent prognostic factor for survival in advanced 
NSCLC patients (p<0.001).
Conclusion: PS is a strong prognostic factor in advanced NSCLC.
Keywords: Performance status, Survival, Advanced non-small cell lung cancer.
INTRODUCTION
Non-small cell lung cancer (NSCLC) is one of the growing public health 
problems in Malaysia. At diagnosis, most patients presented with 
inoperable advanced disease [1]. Locally advanced or metastatic disease 
treatment is palliative not curative. In advanced NSCLC, prognosis is 
the fundamental factor that influences the treatment decisions. Better 
prognostic tools are needed to avoid the use of unnecessary, harmful 
therapy in the end-stage life. Lung cancer treatment guidelines advised 
performance status (PS) as the most established factor for assessing 
prognosis [2].
PS is the assessment of patient’s fitness. It measures the impact of 
tumour symptoms, together with other pre-existing medical problems 
with a patient’s daily life and ability of self-care [3]. In oncologic 
practice, PS is widely used as it correlates with survival duration of 
patients [4]. Two most commonly employed scales are the Karnofsky 
scale [5] created at the beginning of chemotherapy era and the 
Eastern Cooperative Oncology Group scale (ECOG) of PS. ECOG PS is an 
evaluation scale of 0-5 based on the level of symptoms affecting normal 
activity and the proportion of waking hours spent in bed [6]. ECOG PS 
scores are described in Fig. 1. PS is a strong independent prognostic 
factor of survival in advanced NSCLC [7,8].
Numerous studies are available on the prognostic significance of PS in 
advanced NSCLC patients mainly from developed countries. However, to 
date, no such data are published in Kuala Lumpur, Malaysia. Therefore, 
the present study aimed to investigate the prognostic significance of PS 
in advanced NSCLC adult Malaysian patients. Data obtained from this 
study later may help the clinical oncologists and clinical pharmacists, 
especially in Kuala Lumpur, Malaysia, to use ECOG PS as a more effective 
prognostic tool in advanced NSCLC adult Malaysian patients.
METHODS
A retrospective observational study was conducted at Radiotherapy 
and Oncology Clinic, Hospital Kuala Lumpur, Malaysia, between 
1 September 2014 and 31 January 2015. The study was approved by 
Postgraduate Academics and Ethics Committee, Faculty of Pharmacy, 
Universiti Teknologi MARA (UiTM), Research Ethics Committee, 
Research Management Institute and Medical Research and Ethics 
Committee, Ministry of Health, Malaysia.
This study included 163 adult Malaysian patients (≥18 years old) that 
had histological confirmed locally advanced (Stage III A) or metastatic 
(Stage III B, Stage IV) NSCLC and was on chemotherapy treatment. 
Age, gender, body weight, clinical stage, and ECOG PS score were noted 
at the time of diagnosis of disease. To calculate survival time, date of 
diagnosis, date of the last follow-up and date of death were recorded.
Statistical analysis was conducted using SPSS 21.0 version. 
Demographic and medical data variables were analyzed descriptively. 
Pearson χ2 tests were used to find the association of demographic and 
medical data variables with categories of ECOG PS. Multinomial logistic 
regression was carried out to find the relationship of ECOG PS with 
patient’s demographic and medical data. For survival analysis, survival 
time was calculated in days and defined as the time from diagnosis of 
the disease until death or censored if alive or lost follow-up. To evaluate 
the prognostic significance of PS, Kaplan-Meier method was used to 
measure median overall survival (OS) time for EGOG PS scores and 
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log-rank test for comparison of the survival curve. Cox proportional 
hazard regression was run to investigate the effect of the ECOG PS 
scores on death by estimating the hazard ratio. Groups where n≤10 
were not reported. Statistically significant was assumed for a two-tailed 
p<0.01, p<0.05, p<0.001.
RESULTS
There were 163 patients included in the study. The overall mean age 
of enrolled patients was 56.7±10.1 years old. Most were male, having 
overall mean body weight 57.42±13.5 kg and Stage IV NSCLC (Table 1). 
ECOG PS showed significant association with age and body weight 
(Table 2). There was no significant relationship between ECOG PS and 
other independent study variables. Majority patients had an ECOG 
PS of 2 (41.1%) followed by 35.0% having ECOG PS of 3. Univariate 
overall survival analysis for EGOG PS scores of advanced NSCLC 
patients showed that median OS for PS=2 was 377 days, for PS=3 was 
397 days, and for PS=4 was 253 days (Table 3). The difference in OS was 
statistically significant (p=0.003), (Fig. 2). Multivariate analysis showed 
that PS was the predictor of survival in advanced NSCLC patients 
(p<0.001) (Table 3).
DISCUSSION
In the present study, the overall mean age of the study patients at 
presentation was found to be 56.7±10.1 years old. The results obtained 
in two other published Malaysian studies by Liam et al. [9], and Hashim 
et al. [10] stated that overall mean age was 60.3±11.6 years old. The 
differences in the mean age of patients in the present study and 
previously published two studies might be attributed to differences in 
the inclusion-exclusion criteria of study. The present study only involved 
unresectable NSCLC patients while both previously published studies 
included unresectable NSCLC patients along with minor percentages of 
resectable NSCLC patients.
Male gender formed the predominant group of adults NSCLC patients 
(68.7%). Similar results were obtained in different study locations of 
Malaysia by Liam et al. [9], and Hashim et al. [10], where the male was 
more frequently suffering from NSCLC. Youlden et al. [11] stated that 
despite geographical differences, lung cancer had higher incidence 
worldwide among males as compared to females.
The current study showed that at diagnosis, most patients were 
suffering from Stage IV NSCLC. This finding is in agreement with a 
study carried out in Thailand by Kitiporn et al. [12] where Stage IV 
was the most common clinical stage of NSCLC. Increased frequency 
of metastatic NSCLC may be attributed to the late presentation and 
heterogeneous nature of the disease.
Results of Table 2 depicted that ECOG PS was significantly associated 
with age and body weight of adult NSCLC patients. Similarly, Kawaguchi 
et al. [13] in their study on NSCLC patients found a significant association 
Table 1: Patient demographic and medical data
Variable Category Advanced 
NSCLC (n=163)
n (%)






















SD: Standard deviation, NSCLC: Non-small cell lung cancer
Table 2: Association of EGOG PS with advanced NSCLC patient demographic and medical data
Variable ECOG PS scores (n=163), n (%) pa
0 1 2 3 4
Age (Years old)
18-40 0 (0.0) 5 (3.0) 4 (2.4) 3 (1.8) 1 (0.6) 0.008*
41-64 3 (1.8) 22 (13.4) 40 (24.5) 47 (28.8) 6 (3.6)
≥65 0 (0.0) 2 (1.2) 23 (14.1) 7 (4.2) 0 (0.0)
Gender
Male 3 (1.8) 18 (11.0) 45 (27.6) 40 (24.5) 6 (3.6) 0.556
Female 0 (0.0) 11 (6.7) 22 (13.4) 17 (10.4) 1 (0.6)
Body weight (kg)
30-60 3 (1.8) 19 (11.6) 42 (25.7) 39 (23.9) 3 (1.8) 0.018**
61-90 0 (0.0) 7 (4.2) 25 (15.3) 18 (11.0) 4 (2.4)
≥91 0 (0.0) 3 (1.8) 0 (0.0) 0 (0.0) 0 (0.0)
NSCLC Stage
III A 1 (0.6) 7 (4.2) 4 (2.4) 6 (3.6) 0 (0.0) 0.367
III B 1 (0.6) 4 (2.4) 21 (12.8) 13 (7.9) 0 (0.0)
IV 1 (0.6) 18 (11.0) 42 (25.7) 38 (23.3) 7 (4.2)
aChi-square test, *p<0.01, **p<0.05, NSCLC: Non-small cell lung cancer, ECOG: Eastern Cooperative Oncology Group, PS: Performance status
Table 3: Impact of PS on survival in advanced NSCLC patients
Variable n (%) Univariate Multivariate
Median OS (days) pb HR (95% CI) pc
ECOG PS
0 3 (1.8) - 0.003* 5.101 (3.291-7.907) 0.000**
1 29 (17.8) - 0.297 (0.057-1.542) 0.000**
2 67 (41.1) 377 0.320 (0.157-0.655) 0.149
3 57 (35.0) 397 1.117 (0.712-1.753) 0.002*
4a 7 (4.3) 253 - 0.631
aReference group in multivariate analysis, bKaplan-Meier method, cCox proportional hazard regression, *p<0.01, **p<0.001, ECOG: Eastern Cooperative Oncology Group, 
PS: Performance status, OS: Overall survival, HR: Hazard ratio, CI: Confidence interval
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of ECOG PS with age. Patients on diagnosis having body weight <61 kg 
were more frequently having EGOG PS score of 2 (25.7%) followed by 
ECOG PS score of 3 (23.9%). Dewys et al. [14] stated that poor body 
weight was associated with decreased PS.
The present study demonstrated that patients with ECOG PS score of 4 
had worse survival which was similar to the study by Simmons et al. [8] 
who also observed least survival among patients having ECOG PS score 
of 4. The findings of the Cox proportional hazard model suggested 
that hazard to death was decreased in patients with ECOG PS 0 and 
increased in patients with ECOG PS 2. Likewise, Radzikowska et al. [15] 
also found that survival was worse in ECOG PS 2 patients as compared 
to patients with ECOG PS score of 0. Hence, both current and later study 
confirmed PS as a significant independent prognostic factor for survival 
in advanced NSCLC.
CONCLUSION
PS is a strong prognostic factor of survival in advanced NSCLC. In 
translating this to clinical care, PS should be examined in the setting of 
treatment stratification among advanced NSCLC patients.
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Fig. 1: Eastern Cooperative Oncology Group, performance status 
scores description
Fig. 2: Kaplan-Meier survival curve for Eastern Cooperative 
Oncology Group, performance status scores
